Sign In
Buy TAK
$15.03
-0.150 (-0.99%)
At Close: Jun 03, 2026
OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the first quarter of fiscal year 2024 (period ended June 30, 2024), with continued momentum in its Grow
3 Biotech Stocks to Buy on the Dip: July 2024
06:00am, Monday, 29'th Jul 2024
The biotechnology sector doesn't need to rizz up investors, as the kids like to say. Unless the human desire to find solutions for vexing conditions and diseases somehow goes away in a dystopian parad
AC Immune: Takeda Partnership Brings Funds To Drive Pipeline Forward
03:10pm, Friday, 26'th Jul 2024
AC Immune SA's Takeda Pharmaceutical Company partnership brought in an upfront payment of $100 million, with the potential to earn up to $2.1 billion in milestone payments. Interim safety and immunoge
Takeda's AI-Powered Strategy To Optimize Operations And Accelerate Its Pipeline
09:56am, Friday, 19'th Jul 2024
Takeda Pharmaceutical Company Limited showed signs of improvement despite revenue declines in oncology and neurosciences, thanks to gains in gastrointestinal and inflammation sectors and strategic lea
3 Biotech Stocks For The Second Half Of 2024
04:48pm, Thursday, 27'th Jun 2024
3 Biotech Stocks For The Second Half Of 2024
Takeda Announces New Assignments of Directors
03:05am, Wednesday, 26'th Jun 2024
OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) has announced new assignments of directors, determined at the Board of Directors meeting and at the Audit and Supervisory Committee meeting,
Takeda To Keep Pushing for China Biotech Partnership
08:09pm, Tuesday, 25'th Jun 2024
Takeda Pharmaceutical will continue efforts to forge partnerships with Chinese biotech companies even with some tensions between US and China. Speaking exclusively to Bloomberg, CEO Christophe Weber s
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that LIVTENCITY® (maribavir) has been approved by the Japanese Ministry of Health, Labour and Welfare (MHL
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today presented positive results from its Phase 2b, randomized, double-blind, placebo-controlled study evaluating the safet
Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer
04:00pm, Friday, 21'st Jun 2024
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) approved FRUZAQLA (fruquintinib) as a monotherapy indicated for the treat
Takeda gives Sun Pharma, Cipla rights to commercialize gastro drug in India
01:47am, Friday, 21'st Jun 2024
Japan's Takeda Pharmaceutical gave India's Sun Pharmaceutical and Cipla the rights to commercialize gastrointestinal drug Vonoprazan in the country.
Ascentage Pharma Announces Closing of US$75 Million Equity Investment by Takeda
09:15pm, Thursday, 20'th Jun 2024
ROCKVILLE, Md. and SUZHOU, China , June 20, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (C
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced data from the Phase 3 ADVANCE-CIDP 3 clinical trial, a long-term extension study evaluating the safety and
What's Going On With Ovid Therapeutics After Takeda's Two Phase 3 Epilepsy Studies Fail?
08:58am, Monday, 17'th Jun 2024
Monday, Takeda Pharmaceutical Co Ltd TAK announced topline data from its SKYLINE and SKYWAY Phase 3 studies of Soticlestat (TAK-935) for the treatment of Dravet syndrome (DS) and Lennox-Gastaut syndro
Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome
06:45am, Monday, 17'th Jun 2024
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced topline data from its SKYLINE and SKYWAY studies. SKYLINE (TAK-935-3001) was a multicenter, randomized, dou
